[{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Istradefylline","moa":"Adenosine A2a receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kyowa Hakko Bio \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Hakko Bio \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Istradefylline","moa":"Adenosine A2a receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kyowa Hakko Bio \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Hakko Bio \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Istradefylline","moa":"Adenosine A2a receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kyowa Hakko Bio \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Hakko Bio \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Istradefylline","moa":"Adenosine A2a receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kyowa Hakko Bio \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"6","companyTruncated":"Kyowa Hakko Bio \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Istradefylline","moa":"Adenosine A2a receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Hakko Bio \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"6","companyTruncated":"Kyowa Hakko Bio \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Mogamulizumab","moa":"C-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase II","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyowa Hakko Bio \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Hakko Bio \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Mogamulizumab","moa":"C-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase II","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Hakko Bio \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Hakko Bio \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Mogamulizumab","moa":"C-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Hakko Bio \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"7","companyTruncated":"Kyowa Hakko Bio \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Mogamulizumab","moa":"C-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Hakko Bio \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"6","companyTruncated":"Kyowa Hakko Bio \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"KRN23","moa":"Fibroblast growth factor 23","graph1":"Rare Diseases and Disorders","graph2":"Phase IV","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Hakko Bio \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"11","companyTruncated":"Kyowa Hakko Bio \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Kyowa Hakko Bio","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Citrulline","moa":"G-protein coupled receptor GPCR33 (GPRC6A)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Hakko Bio \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Hakko Bio \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"KW-2478","moa":"Heat shock protein 90 alpha (HSP90A)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Hakko Bio \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"7","companyTruncated":"Kyowa Hakko Bio \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Kyowa Hakko Bio","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Setria Glutathione","moa":"Immunostimulant","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Hakko Bio \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Hakko Bio \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Kyowa Hakko Bio","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Setria Glutathione","moa":"Immunostimulant","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Hakko Bio \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Hakko Bio \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"KW-2450","moa":"Insulin-like growth factor I receptor | Insulin receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Hakko Bio \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"6","companyTruncated":"Kyowa Hakko Bio \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"University of Cincinnati","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Citicoline Sodium","moa":"LicC protein","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Hakko Bio \/ University of Cincinnati","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Hakko Bio \/ University of Cincinnati"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Biofortis Clinical Research, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Citicoline Sodium","moa":"LicC protein","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Hakko Bio \/ Biofortis Clinical Research, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Hakko Bio \/ Biofortis Clinical Research, Inc."},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Oregon Health and Science University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Citicoline Sodium","moa":"LicC protein","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Hakko Bio \/ Oregon Health and Science University","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Hakko Bio \/ Oregon Health and Science University"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"KHK2866","moa":"Proheparin-binding EGF-like growth factor","graph1":"Oncology","graph2":"Phase I","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Hakko Bio \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"6","companyTruncated":"Kyowa Hakko Bio \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"HMO","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Hakko Bio \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Hakko Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"KHK6640","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Hakko Bio \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"6","companyTruncated":"Kyowa Hakko Bio \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Kyowa Hakko Bio","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Alanyl Glutamine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Hakko Bio \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Hakko Bio \/ Kyowa Hakko Bio"},{"orgOrder":0,"company":"Kyowa Hakko Bio","sponsor":"Kyowa Hakko Bio","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Kyowa Hakko Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Hakko Bio \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Hakko Bio \/ Kyowa Hakko Bio"}]

Find Clinical Drug Pipeline Developments & Deals by Kyowa Hakko Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Mogamulizumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Mycosis Fungoides.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          January 31, 2024

                          Lead Product(s) : Mogamulizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Moffitt Cancer Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : HMO is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Gastrointestinal Diseases.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          October 23, 2023

                          Lead Product(s) : HMO

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : L-Citrulline is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Menopause.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          December 17, 2020

                          Lead Product(s) : Citrulline

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Undisclosed

                          Recipient : Texas Tech University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : This drug candidate is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 26, 2019

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Recipient : Loughborough University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Citicoline is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          February 23, 2018

                          Lead Product(s) : Citicoline Sodium

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Oregon Health and Science University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Citicoline is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          December 12, 2017

                          Lead Product(s) : Citicoline Sodium

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Biofortis Clinical Research, Inc.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Citicoline is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          March 10, 2016

                          Lead Product(s) : Citicoline Sodium

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : University of Cincinnati

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Istradefylline is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Parkinson Disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 20, 2015

                          Lead Product(s) : Istradefylline

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Recipient : Kyowa Kirin

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Istradefylline is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Substance-Related Disorders.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 20, 2015

                          Lead Product(s) : Istradefylline

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Recipient : Kyowa Kirin

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Setria Glutathione is a Peptide drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          May 08, 2015

                          Lead Product(s) : Setria Glutathione

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Recipient : University of Florida

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank